Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...
Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
For the newer 7.0 version and MR-BMS771 (7S - 14S) board support, see https://github.com/NXPHoverGames/MR-BMS771. For the RDDRONE-BMS772 MATLAB Simulink MBDT BMS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback